Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

Pacira

Status and phase: Completed; Phase 2

Conditions: Osteoarthritis of the Shoulder; Osteoarthritis of the Hip

Treatments: Drug: TAcs 40 mg; Drug: FX006 32 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT03382262

FX006-2017-013

Details and patient eligibility

About

This is an open-label study to compare systemic exposure to triamcinolone acetonide following a dose of extended-release FX006 or immediate-release TAcs (triamcinolone acetonide suspension) in patients with osteoarthritis of the shoulder (glenohumeral joint) or hip

Full description

This is a randomized, open-label, single dose study that will be conducted in male and female patients ≥40 years of age with OA of either the shoulder or the hip.

Approximately 24 patients with OA of the shoulder and approximately 24 patients with OA of the hip will be randomized to one of two treatment groups (1:1) and treated with a single IA injection of either:

• 32 mg FX006 (approximately 12 patients per joint) or
• 40 mg TAcs (approximately 12 patients per joint)

Each patient will be screened to confirm the diagnosis of OA of either the shoulder or hip and eligibility based on the other inclusion/exclusion requirements and will be randomized to treatment on Day 1. Each patient will be evaluated for a total of 12 weeks following the IA injection. Following screening, sampling for pharmacokinetics (PK) and safety will be completed at 10 out-patient visits scheduled on Study Days 1 [calendar day of injection], 2, 3, 5, 8, 15, 22, 29, 57, and 85.

Enrollment: 55 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written consent to participate in the study
• Male or female greater than or equal to 40 years of age
• Body mass index (BMI) less than or equal to 40 kg/m2
• Ambulatory and in good general health
• Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions
• Willing to abstain from use of protocol-restricted treatments from Screening through End-of-Study visit
• Symptoms consistent with OA of the index joint for ≥ 6 months prior to Screening (patient reported is acceptable)
• Pain in the index joint for greater than15 days over the last month (as reported by the patient)
• For Shoulder OA patients: Radiologic findings of OA of the index shoulder meeting the Samilson-Prieto (S-P) Classification Grades 2 or 3
• For Hip OA patients: ACR Criteria (clinical and radiological) for OA of the index hip

Exclusion criteria

• Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
• History of infection in the index joint
• Clinical findings consistent with active infection or crystal disease in the index joint within 1 month of Screening
• History of fracture in the index limb within 12 months of Screening, or fracture with sequelae at any time
• Planned or anticipated surgery of the index joint during the study period
• Index joint instability or history of acute dislocation within 12 months of Screening
• If shoulder is the index joint, history of full or partial rotator cuff tear or significantly compromised rotator cuff function that, in the opinion for the Investigator, increases the difficulty or risk of IA injection
• Presence of surgical hardware or other foreign body in the index joint
• Surgery or arthroscopy of the index joint within 12 months of Screening
• IA treatment of any joint with any of the following agents within 6 months of Screening:
• Any corticosteroid preparation (investigational or marketed, including FX006), any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed)
• IA treatment of the index joint with hyaluronic acid (investigational or marketed) within 6 months of Screening
• Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening
• Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
• Females who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

55 participants in 2 patient groups

FX006 32 mg

Experimental group

Description:

Single intra-articular (IA) injection of FX006 32 mg

Treatment:

Drug: FX006 32 mg

TAcs 40 mg

Active Comparator group

Description:

Single intra-articular (IA) injection of TAcs 40 mg

Treatment:

Drug: TAcs 40 mg